Cantor Fitzgerald Comments on Insmed FY2025 Earnings

Insmed, Inc. (NASDAQ:INSM) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Insmed in a research report issued on Tuesday, October 28th. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share of ($5.09) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $192.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. Cantor Fitzgerald also issued estimates for Insmed’s FY2026 earnings at ($2.86) EPS.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS.

Several other research firms have also issued reports on INSM. Guggenheim boosted their price target on shares of Insmed from $125.00 to $172.00 and gave the company a “buy” rating in a research report on Monday, September 8th. JPMorgan Chase & Co. boosted their target price on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Wednesday, October 8th. Morgan Stanley boosted their price objective on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, The Goldman Sachs Group boosted their price objective on Insmed from $121.00 to $196.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $161.59.

Insmed Trading Up 16.3%

Shares of Insmed stock opened at $194.22 on Thursday. Insmed has a 52-week low of $60.40 and a 52-week high of $194.70. The stock’s 50-day simple moving average is $150.86 and its 200 day simple moving average is $111.26. The stock has a market capitalization of $41.05 billion, a P/E ratio of -34.01 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the company’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $145.45, for a total value of $11,129,834.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at $5,303,252.45. This represents a 67.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 6,865 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $128.40, for a total transaction of $881,466.00. Following the completion of the transaction, the chief executive officer owned 233,924 shares in the company, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 152,657 shares of company stock valued at $21,442,198. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. increased its holdings in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the last quarter. ORG Partners LLC increased its holdings in shares of Insmed by 220.2% in the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares during the last quarter. Hilltop National Bank bought a new position in shares of Insmed in the 2nd quarter worth $28,000. Stone House Investment Management LLC bought a new position in shares of Insmed in the 3rd quarter worth $29,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.